

REPAIR-MDS Newsletter



February & March 2023, Issue 12&13

Achievements ★

In February,
East Kent and Canterbury Hospital and **Heartlands Hospital** registered a patient each.

In March,
Russell's Hall Hospital and **Leicester Royal Infirmary** have registered a patient each & **Good Hope Hospital** have randomised a patient.

A huge thank you to the site teams for their support!

Recruitment Update

- 23 Registrations
- 14 Randomisations
- 14 Sites open to recruitment

Target to reach 10 patients randomised to either arm for Safety Milestone

WE NEED YOUR HELP TO REACH THIS MILESTONE!

Blood Cancer UK Walk of Light

The REPAIR-MDS Trial Chief Investigators **Dr Steve Jenkins** and **Dr Manoj Raghavan**, along with Co-Investigator **Professor Chris Bunce**, took part in the Blood Cancer UK Walk of Light on **Saturday 25th March**.

Armed with lanterns, fundraisers walked either 2.5 or 5km around Cannon Hill Park in Birmingham just after sundown in support of the charity. Although a little chilly it was a lovely evening and Trial Manager Beth was pleased to be there to cheer the team on!

Blood Cancer UK is integral in raising awareness, supporting patients and their families living with many types of blood cancer and other blood disorders along with supporting vital clinical research to improve outcomes, just like the REPAIR-MDS Trial.

Thank you to all who helped fundraising the total amount of **£935!**




REPAIRMDS

REPAIR-MDS Trials Team: 02476 575 675 | E-mail: repairMDS@warwick.ac.uk |

Twitter: [@REPAIR_MDS](https://twitter.com/REPAIR_MDS) / Twitter |

Website: [REPAIR MDS \(warwick.ac.uk\)](http://REPAIR_MDS(warwick.ac.uk))





Clinical Immunology Service - Easter Closure

The Clinical Immunology Service will be closing over the Easter Period:

**Friday 7th April to
Wednesday 12th April**

Do not post samples for science to the Clinical Immunology Service until:
Thursday 13th April

Please re-arrange sample collection as appropriate and get in touch with the Trial Team if this is not possible. Apologies for any inconvenience this may cause.

Investigator Meeting

Thank you to those who attended the session on **17th March**. The team covered an overview of the cautionary observation and management of oedema for VBaP patients & Key updates of upcoming Substantial Amendment 4.0 (which has now been approved & will be circulated to sites).

For those who were not able to attend, a recording of the session is available on the REPAIR-MDS Trial website here:

[investigatormeetings \(warwick.ac.uk\)](https://investigatormeetings.warwick.ac.uk)

The slide-set can be made available upon request. Please email the trial team for more information.

Change in pack size - Sodium Valproate 200mg

Due to stock availability, there was a change in supplier of Sodium Valproate 200mgs as part of the REPAIR-MDS study. For any future orders of Sodium Valproate 200mgs the **Wockhardt** brand will be supplied and will have a **pack size of 100 tablets**.

The current approved IMP Dossier includes the SmPCs for both brands, therefore no IMPD updates were required.

Sodium Valproate 200mg Gastro-Resistant Tablets Wockhardt and Epilim brands may be used interchangeably depending on stock availability.

What do you need to do?

If you have not already, please:

- Update prescription template and file a copy within folder 8.1 of the PSF. **Return a copy of the updated prescription template to:**

RepairMDS@warwick.ac.uk

- Add updated documents circulated on 29-Mar-2023 to your ISF and PSF and mark previous versions as superseded.
- Reply to the notice circulated on 29-Mar-2023 to confirm that previous versions of documents have been superseded and new documents have been filled as appropriate.



The RepairMDS Trial Team wishes you a Happy Easter!
Best Easter wishes to you and yours this festive spring season.

